13/09/2026 First-time outcomes from the failed Ph3 EVOKE-03 study of sacituzumab govitecan-hziy+ pembro in Tx naive PD-L1 ≥50% NSCLC pts presented at WCLC'26 First-time outcomes from the failed Ph3 EVOKE-03 study of sacituzumab govitecan-hziy+ pembro in Tx naive PD-L1 ≥50% NSCLC pts presented at WCLC'26 (abstract #PL02.06; Ref) The first reported efficacy and safety outcomes from the Ph3 KEYNOTE-D46/EVOKE-03 trial of Gilead's sacituzumab govitecan-hziy (SG; TROP2 ADC) + Merck

21/04/2026 Phase 3 LITESPARK-012: Triplet and Doublet Regimens Fail to Surpass KEYTRUDA + LENVIMA in Advanced RCC Phase 3 LITESPARK-012: Triplet and Doublet Regimens Fail to Surpass KEYTRUDA + LENVIMA in Advanced RCC (Ref) Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for first-line treatment of advanced clear cell RCC. Both experimental combination re